Spots Global Cancer Trial Database for lutathera
Every month we try and update this database with for lutathera cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | NCT03971461 | Meningioma | Lutathera | 18 Years - | NYU Langone Health | |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | NCT03325816 | Small Cell Lung... Small Cell Lung... | Nivolumab 177Lu-DOTA0-Tyr... | 18 Years - | Georgetown University | |
| Post-Authorization Long-Term Safety Study of LUTATHERA | NCT03691064 | Neuroendocrine ... | LUTATHERA | 18 Years - | Advanced Accelerator Applications | |
| Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases | NCT05987176 | Neuroendocrine ... | Lutathera | 18 Years - | Imperial College London | |
| Lutathera and ASTX727 in Neuroendocrine Tumours | NCT05178693 | Neuroendocrine ... | ASTX727 Lutathera | 18 Years - 99 Years | Imperial College London | |
| Biomarker Identification of Radionuclide Therapy-induced Radiation Responses | NCT05513469 | Neuroendocrine ... | Lutathera | 18 Years - 100 Years | Erasmus Medical Center | |
| Biomarker Identification of Radionuclide Therapy-induced Radiation Responses | NCT05513469 | Neuroendocrine ... | Lutathera | 18 Years - 100 Years | Erasmus Medical Center | |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | NCT03325816 | Small Cell Lung... Small Cell Lung... | Nivolumab 177Lu-DOTA0-Tyr... | 18 Years - | Georgetown University | |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | NCT04954820 | Neuroendocrine ... Intestinal Well... Progressive Dis... | Lutathera | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | NCT03971461 | Meningioma | Lutathera | 18 Years - | NYU Langone Health | |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET | NCT03972488 | Gastro-enteropa... | Lutathera long-acting oct... high dose long-... Optional post-p... Optional post-p... Optional post-p... | 15 Years - | Advanced Accelerator Applications | |
| A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors | NCT04614766 | Gastro-enteropa... Neuroendocrine ... | Lutathera Azedra | 18 Years - 80 Years | University of Iowa | |
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea | NCT04946305 | Somatostatin Re... | Lutathera | 18 Years - | Novartis | |
| LUTATHERA Injection General Use Result Survey | NCT05844332 | Somatostatin Re... | LUTATHERA | 18 Years - 99 Years | Novartis | |
| Post-Authorization Long-Term Safety Study of LUTATHERA | NCT03691064 | Neuroendocrine ... | LUTATHERA | 18 Years - | Advanced Accelerator Applications | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy | NCT04039516 | Carcinoid Heart... Carcinoid Syndr... Carcinoid Tumor | Lutathera | 18 Years - | King's College Hospital NHS Trust | |
| A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea | NCT04946305 | Somatostatin Re... | Lutathera | 18 Years - | Novartis | |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | NCT05278208 | High Grade Glio... Meningioma Embryonal Tumor Medulloblastoma Anaplastic Epen... Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim... | LUTATHERA® (Lut... | 4 Years - | Nationwide Children's Hospital | |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy | NCT04039516 | Carcinoid Heart... Carcinoid Syndr... Carcinoid Tumor | Lutathera | 18 Years - | King's College Hospital NHS Trust |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
